Jonathon B. Cohen, MD, MS
Advertisement
Articles by Jonathon B. Cohen, MD, MS
Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.
Advertisement
Latest Updated Articles
Case Assessment: 68-Year-Old Patient With MCLPublished: May 18th 2020 | Updated:
Relapsed Mantle Cell Lymphoma Treatment LandscapePublished: May 18th 2020 | Updated:
Diagnosing MCL and Making Informed Treatment DecisionsPublished: May 18th 2020 | Updated:
Administration of BTK Inhibitors for Mantle Cell LymphomaPublished: May 18th 2020 | Updated:
Initiating Therapy for Mantle Cell LymphomaPublished: May 18th 2020 | Updated:
BTK Inhibitor Toxicities in Mantle Cell LymphomaPublished: May 18th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5
